



Savannah River Site Nuclear Laboratory (SRNL) Technology Insertion

Phillip "Tony" Polk

Director, Savannah River Laboratory Office

Briefing for National Academy of Science Review February 9, 2021

Technology Insertion: Next Generation Solvent – an unparalleled success



SRS SWPF

- -Capital Cost: \$2.3B
- -Original Design Throughput ~ 7M gal/yr
- -Throughput with Next Gen Solvent 9+M gal/yr
- -Planned for SWPF insertion in 2023



SRS Interim Salt Processing Facility-ARP/MCU


- Capital Cost: \$100M
- Cumulative Salt Solution Processed: 3.56 Mgal
- Throughput with Next Gen Solvent validated at ~9+M gal/yr SWPF equivalent

Science, Technology & Innovation:

- Next Generation Solvent
- Centrifugal Contactor

Integrated effort:

ORNL, SRNL, Argonne, PNNL, Idaho



Technology Insertion: Tank Closure Cesium Removal (TCCR)



Process Enclosure



Crystalline silicotitanate

sintered metal dead-end filter assembly

Ion Exchange Columns

TCCR Project

\$34 M for TCCR ~500 kgal/y

(operational; 30 months to reach deployment)

\$17M for upgrades (TCCR-1A) in progress TCCR-2 ~1 Mgal /y

Start of Demonstration 16 Jan 2019

Volume processed 300 kgal (complete)


Supplemental to SWPF Processing (Target: 5 Mgal) independent of DWPF

Parallel program at Hanford (TSCR).

Science, Technology & Innovation:

- Ion exchange media development
- Media preparation
- Gamma monitor in-line measurements
- Performance and thermal modeling platforms
- Feed qualification and process verification samples
- Capacity/loading testing
- Integration into System / Downstream Impacts
- Safety Basis fundamentals
- Maturation of technology over >20 years





SRS T-Area (2008) -- Transition strategy for transition from active Pump and Treat to Passive Treatment with Edible Oil designed and implemented

- Regulatory approval of remedy led to site closure
- Strategy transferred to DOE Legacy Site, Mound, Ohio (2014)
- Estimated duration for Pump and Treat to closure was 21 years
- SRNL provided site-specific design information and consulting for strategy implementation
- After implementation, SRNL provided annual data review and performance analysis
- Regulatory approval for transition to passive remedy granted in 2020